Entering text into the input field will update the search result below

Editas Medicine, Inc.'s (EDIT) Management Presents At 4th Annual Evercore ISI HealthCONx Conference (Transcript)

Dec. 02, 2021 11:46 AM ETEditas Medicine, Inc. (EDIT)
SA Transcripts profile picture
SA Transcripts

Editas Medicine, Inc. (NASDAQ:EDIT) 4th Annual Evercore ISI HealthCONx Conference December 2, 2021 9:40 AM ET

Company Participants

Mark Shearman - Chief Scientific Officer

Lisa Michaels - Chief Medical Officer

Conference Call Participants

Liisa Bayko - Evercore ISI

Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.

Liisa Bayko

00:01 Hi, there. Good morning. This is Liisa Bayko, Biotech Analyst at Evercore ISI. Very pleased to be joined by one of the leading CRISPR companies Editas Medicine’s. We have two of the Medical Scientific kind of tied from the call with us Lisa Michaels and Mark Shearman, who are going to go through some of the pipeline questions. But I just wanted to start off by sort of a broad question and I'm kind of asked this all the CRISPR companies that I'm talking to over the course of our conference, but as I reflect on CRISPR kind of where it started, right? It's just taken so many different forms. So, know you guys are initially focused on Eye (ph) and you've got some other, ex-vivo output, some people started with ex-vivo are going down.

00:49 The route of CAR-T and then others are regenerative medicine and other people are focused on in vivo as an initiation, sort of what was your like, how did you come to the notion that you kind of start with the Eye and sort of go from there, the idea there?

Mark Shearman

01:09 Well, I will take a stab at that explaining, I think the logic of our -- mine and Lisa’s predecessor of the company, but I think

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About EDIT

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on EDIT

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.